MOGENRY Therapy: How does MOGENRY Therapy work, and how much benefit will Indians get?
- bySherya
- 18 Nov, 2026
MOGENRY gene therapy is offering new hope for patients who have lost their eyesight due to a serious retinal disease. Learn how this technology works and how it can benefit people.
How does Mogenari therapy work?
Eye-related diseases are becoming a major problem for people these days. Some diseases gradually cause vision loss, significantly impacting the patient's vision. One such condition is Retinitis Pigmentosa, in which the light-detecting cells in the retina gradually deteriorate. Severe forms of this disease can lead to blindness.
But now, scientists have developed a new gene therapy called MOGENRY for patients suffering from this disease. According to recent reports, this technology has improved vision in some patients. This news is also important for India, where the number of people affected by this disease is said to be quite high.
What is Mogenry Therapy?
MOGENRY is a type of Optogenetic Gene Therapy. Developed by the US company Nanoscope Therapeutics, it aims to help patients with Retinitis Pigmentosa, whose light-sensing eye cells, known as photoreceptors, have been damaged. Typically, gene therapy attempts to repair or replace the disease-causing defective gene. However, MOGENRY's approach is slightly different. It attempts to make light-sensitive cells in the eye that are still alive despite the disease. This way, it helps other cells to replace the damaged photoreceptors.
This is how this therapy works.
This technique involves introducing a specific light-sensitive gene into the eye. A virus, considered safe, is used as a medium to deliver this gene to the remaining retinal cells. This allows some retinal cells to recognize light. Normally, photoreceptors convert light into electrical signals, which the brain interprets to process vision. However, in Retinitis Pigmentosa, these cells begin to deteriorate. The optogenetic technique used in MOGENRY aims to make the remaining retinal cells light-sensitive, allowing them to transmit visual signals to the brain. This therapy is administered once through an injection into the eye.
People in India can get benefit.
This therapy is also being hoped for in India because of the high number of cases of Retinitis Pigmentosa here. Reports suggest that approximately one in every 4,000 people worldwide is affected by this disease, while in India, the figure is estimated to be one in every 1,000. Based on this estimate, over 1 million people in the country are living with this disease. Therefore, if MOGENRY receives the necessary regulatory approval and proves effective in further trials, it could become an important treatment option for Indian patients. Importantly, it does not rely on correcting a single defective gene. Therefore, it holds promise for patients with Retinitis Pigmentosa caused by various causes.





